The Fed’s regulatory chief recently weighed in on a path to improvement following a string of midsize bank failures. Eli Lilly’s Retatrutide medication was recently under the WSJ spotlight for its surprising results. Rite Aid’s stock just hit a record...
The Fed’s regulatory chief recently weighed in on a path to improvement following a string of midsize bank failures. Eli Lilly’s Retatrutide medication was recently under the WSJ spotlight for its surprising results. Rite Aid’s stock just hit a record low. We’re discussing these topics and more in Episode 11.
------🔎RESOURCES🔎
CPI REPORT //
https://www.bls.gov/news.release/pdf/cpi.pdf ADP JOBS REPORT //
https://adpemploymentreport.com/JOLTS REPORT //
https://www.bls.gov/news.release/jolts.nr0.htmREDBOOK RETAIL REPORT //
https://tradingeconomics.com/united-states/redbook-indexBANKS ARE GOING TO NEED MORE CAPITAL (WSJ) //
https://on.wsj.com/3pNXG5eLILLY'S RETATRUTIDE SHOWS BENEFITS ON FATTY LIVER DISEASE (WSJ) //
https://bit.ly/3XRDyLXRITE-AID DEBT CONCERNS (MARKETWATCH) //
https://bit.ly/3rAYlasMARCUS WHITNEY: BANKING STRUGGLES ARE LIMITING HEALTHCARE INNOVATION //
https://bit.ly/44J4gZo------🔔SIGN UP FOR EPISODE NOTIFICATIONS🔔
https://www.podpage.com/healthfurther/------📱FOLLOW HEALTH:FURTHER SOCIALS📱
INSTAGRAM //
https://www.instagram.com/healthfurther/TWITTER //
https://twitter.com/HealthFurtherFACEBOOK //
https://www.facebook.com/HealthFurther/LINKEDIN //
https://www.linkedin.com/company/health-furtherTIKTOK //
https://www.tiktok.com/@healthfurtherYOUTUBE //
https://www.youtube.com/channel/UCFM4torjTIEkOLOD-p7FIKw
